A Study of Ocrelizumab in Participants With Relapsing Remitting Multiple Sclerosis (RRMS) Who Have Had a Suboptimal Response to an Adequate Course of Disease-Modifying Treatment (DMT)

  • Autoimmune Disorder
  • Multiple Sclerosis (MS)
Please note that the recruitment status of the trial at your site may differ from the overall study status because some study sites may recruit earlier than others.
Trial Status:

Completed

This trial runs in
Countries
  • Australia
  • Belgium
  • Czechia
  • Denmark
  • Estonia
  • Finland
  • France
  • Germany
  • Ireland
  • Italy
  • Netherlands
  • Norway
  • Spain
  • Sweden
  • Switzerland
  • Turkey
  • United Kingdom
Trial Identifier:

NCT02861014 2015-005597-38 MA30005

      Show trial locations

      The source of the below information is public registry websites such as ClinicalTrials.gov, EuClinicalTrials.eu, ISRCTN.com, etc.. It has been summarised and edited into simpler language. For more information about this clinical trial see the For Expert tab on the specific ForPatients page or follow these links to https://clinicaltrials.gov and/or https://euclinicaltrials.eu and/or https://www.isrctn.com.

      The below information is taken directly from public registry websites such as ClinicalTrials.gov, EuClinicalTrials.eu, ISRCTN.com, etc., and has not been edited.

      Results Disclaimer

      Trial Summary

      The purpose of this prospective, multicenter, open-label, efficacy, and safety study is to assess the efficacy and safety of ocrelizumab in participants with Relapsing Remitting Multiple Sclerosis (RRMS) who have had a suboptimal response to an adequate course of a Disease-Modifying Treatment (DMT). The study will consist of a Screening period (up to 4 weeks), an Open-label treatment period (96 weeks; with last dose administered at Week 72), and a Follow-up period of at least 2 years.

      Hoffmann-La Roche Sponsor
      Phase 3 Phase
      NCT02861014,MA30005,2015-005597-38 Trial Identifier
      Ocrelizumab Treatments
      Multiple Sclerosis, Relapsing-Remitting Condition
      Official Title

      An Open-Label Study To Evaluate the Efficacy and Safety of Ocrelizumab in Patients With Relapsing Multiple Sclerosis Who Have A Suboptimal Response to an Adequate Course of Disease-Modifying Treatment

      Eligibility criteria

      All Gender
      ≥18 Years & ≤ 55 Years Age
      No Healthy Volunteers
      Inclusion Criteria
      • Have a definite diagnosis of RRMS, confirmed as per the revised McDonald 2010 criteria
      • Have a length of disease duration, from first symptom, of less than (<) 10 years
      • Have received no more than two prior DMTs, and the discontinuation of the most recent DMT was due to lack of efficacy
      • Suboptimal disease control while on a DMT
      • Expanded Disability Status Scale (EDSS) of 0.0 to 4.0, inclusive, at Screening
      • For women of childbearing potential: agreement to use an acceptable birth control method during the treatment period and for at least 6 months after the last dose of study drug
      Exclusion Criteria
      • Secondary progressive multiple sclerosis (SPMS) or history of primary progressive or progressive relapsing multiple sclerosis (MS)
      • Inability to complete an Magnetic Resonance Imaging (MRI) procedure
      • Known presence of other neurological disorders
      • Any concomitant disease that may require chronic treatment with systemic corticosteroids or immunosuppressants during the course of the study
      • History or currently active primary or secondary immunodeficiency
      • History of severe allergic or anaphylactic reactions to humanized or murine monoclonal antibodies
      • History of opportunistic infections
      • History or known presence of recurrent or chronic infection
      • History of malignancy
      • Congestive heart failure
      • Known active bacterial, viral, fungal, mycobacterial infection or other infection, excluding fungal infection of nail beds

      Clinical Research Explained

      Information about what clinical trials and observational studies are. Understand why you might want to take part in clinical research and why diversity in clinical research is important.

      Find out now